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Abstract 
 
The TRPM8-agonist L-menthol has been used traditionally for its topical counter-irritant properties. 
While the use of topical L-menthol for pain is casuistically established, evidence regarding its efficacy 
is negligible. This study aimed to characterize the eff ct of L-menthol as a counter-irritant on 
cutaneous pain and hyperalgesia provoked by topical application of the TRPA1-agonist trans-
cinnamaldehyde (CA). In a randomized, double-blinded study CA was applied to a 3x3cm area of the 
volar forearm evoking neurogenic inflammation, pain, mechanical and thermal hyperalgesia in 14 
healthy volunteers. In one of two sessions, 1) 10% CA alone, 2) 40% L-menthol + 10% CA applied 
simultaneously were administered for 20min throughout which the subjects rated the pain intensity on a 
VAS0-10. Extensive quantitative sensory testing was conducted and superficial blood flow (neurogenic 
inflammation) was recorded. Administration of CA evoked spontaneous pain, neurogenic 
inflammation, thermal hyperalgesia, and primary andsecondary mechanical hyperalgesia. Co-
administration of topical L-menthol reduced spontaneous pain intensity (P<0.01), neurogenic 
inflammation (P<0.01), primary mechanical hyperalgesia (P<0.05), secondary mechanical hyperalgesia 
(P<0.05), and heat hyperalgesia (P<0.05), but not cold hyperalgesia. L-menthol exhibited inhibitory 
effects on simultaneously established pain, hypersensitivity, and neurogenic inflammation in a human 
TRPA1-induced pain model. Potent TRPM8-agonists could be useful as topical anti-hyperalgesics.  
 
The study and the trial protocol is registered and pproved by the local research ethics committee undr 
the jurisdiction of the Danish Medicines Agency no.: N-20130005. The protocol also is registered at 
Clinicaltrials.gov under the no.: NCT02653703.  
 
Perspective: Drugs interacting with TRP-channels are of great therapeutic potential. In the present 
study we established cutaneous pain and hyperalgesi using the TRPA1-agonist trans-cinnamaldehyde. 
Subsequently, we showed that the frequently used topical counter-irritant and TRPM8-agonist; L-
menthol, decreased evoked pain, hyperalgesia and inflammation, indicating both direct and indirect 
anti-nociceptive mechanisms.  
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1. Introduction 
 
The naturally occurring substance L-menthol is well known to produce a noticeable cooling 
sensation and modest analgesia under certain conditions. The cooling sensation is well-established to 
be a consequence of L-menthol’s sensitization of the cold receptor TRPM8, located primarily on 
cutaneous Aδ-fibers and to a lesser extent C-fibers, while the analgesic properties are far less clear, 
with multiple proposed mechanisms in play.6,46,63 In western medicine, Dr. A. Wright was the first to 
suggest pain-relieving properties of menthol in 1870 in a paper published in The Lancet. He observed 
that topical ointment with peppermint oil (containing L-menthol) reduced pain in patients suffering 
from post-herpetic neuralgia and several studies have since substantiated the claim.15,19,39,44,45,65 Today, 
L-menthol is widely used in ointments to counteract lo al inflammation, eczema and joint aches, in 
lozenges to relieve throat soreness and also in nasal sprays to decongest and de-inflame the upper 
airways in case of common colds and fl. Moreover, FDA has listed L-menthol as a local anesthetic, 
antipruritic and antitussive compound.18 Most usage is subclinical and it is unclear whether  
counter-irritant effects of L-menthol share a similar mechanism between various target tissues to which 
it is routinely applied.  
Paradoxically, numerous recent studies (reviewed in 3) describing the somatosensory alterations 
induced by high concentrations of topical L-menthol ave found that the substance is capable of 
inducing prolonged cold hyperalgesia, spontaneous pain and primary and secondary hyperalgesia. As 
such, labeling L-menthol as a counter-irritant is seemingly more accurate than labeling it as a local 
anesthetic. The relative promiscuity among the natural ransient receptor potential (TRP) channels 
agonists is also applicable for L-menthol, which interacts with several TRP-channels besides TRPM8 
as well as other receptors often in a concentration-dependent manner.20,33,44,45. However, a recent pre-
clinical study convincingly ascertained TRPM8 to be th  principal mediator of L-menthol-induced 
analgesia.45 Despite the widespread recognition of L-menthol’s moderate pain-relieving properties to 
pre-existing painful or pruritic conditions, very little is known with regards to the characteristics of 
these anti-irritant effects and potential underlying mechanisms in humans.  
 
This study aimed at assessing the counter-irritant properties of topical L-menthol on neurogenic 
inflammation, primary and secondary mechanical hyperalg sia and thermal hyperalgesia established by 
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the local irritant trans-cinnamaldehyde (CA). CA works by sensitizing the thermo-receptive and 
inflammation-facilitatory ion-channel TRPA1.57 Topical application of 10% CA has previously been 
shown to cause mild to moderate pain, mechanical and thermal hyperalgesia and neurogenic 
inflammation in human skin and rodents.23,40,43,66 At lower concentrations, topical CA has been found 
to evoke itch in rodents and also in humans.25,66 The primary outcome of this study was CA-evoked 
peak pain intensity monitored for 20 min post application, with versus without L-menthol co-
application, while secondary outcome measures included quantitative sensory testing (QST) parameters 
and neurogenic inflammation. 
This study is the first to present a comprehensive quantitative somatosensory assessment of the 
counter-irritant and anti-inflammatory properties of topically applied high-concentration of TRPM8-
agonist L-menthol on TRPA1-sensitized human skin, including measurement of secondary 
hyperalgesia and vasomotor reactivity. 
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2. Methods 
 
2.1 Study design and subjects 
A total of 14 healthy subjects including 5 males and 9 females, aged 20–33 years (mean: 23.2 ± 
0.92) were recruited. All subjects were pain-free, without previous known neurological, dermatological 
or musculoskeletal disorders, and were instructed not to consume alcohol, nicotine, caffeine and 
medication of any kind 24 h prior to the experiment. All subjects signed a statement of informed 
consent in accordance with the Helsinki Declaration, before participation. The regional ethics 
committee approved the experiment (study no.: N-2013- 005). The same investigator (HHA) 
conducted all experimental sessions. The study was carried out in a double-blinded manner with 
balanced randomization of both the order of substances applied and dominant versus non-dominant 
arm (See fig. 1 for an overview of the study design and notice simultaneous application of L-menthol + 
CA). Hence, both the investigator and the subjects were blinded to the substance being applied. Two 
cotton pads soaked in a solution of 40%(w/v) L-menthol + 10%(v/v) CA were placed in the laboratory 
20 min before the onset of testing. This was done t create an overwhelming ambient smell of both of 
the applied substances, in order to inhibit the investigator and participants ability to identify the order 
of solutions investigated by olfaction. Such a procedure has previously been utilized in previous studies 
using highly odorous compounds to avoid unmasking the investigator and subjects.24,40,43 The ambient 
temperature was kept at ≈21 °C in all experimental sessions. 
 
2.2. Application of CA and L-menthol 
CA (≥99%) and L-menthol (≥99.9%) were obtained from Sigma Aldrich (Broendby, Denmark) 
and dissolved in 90% ethanol at concentrations of 10%(v/v) CA and 40%(w/v) L-menthol + 10%(v/v) 
CA. The chosen concentrations were determined by precedence in the literature showing that 10% CA 
evokes a considerable neurogenic flare and prolonged mechanical hyperalgesia 39,40,43 and that the 
maximal solubility of pure L-menthol in ethanol is approximately 40%. Ethanol was chosen as a 
vehicle because of 1) its ability to dissolve a high concentration of L-menthol, 2) its low toxicity for an 
organic solvent, 3) its marginal somatosensory sensory effects and 4) the precedence of using it in 
literature.3,4,39,40,43 
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One mL aliquot of each test substance was dispensed onto a 3 × 3 cm cotton pad and placed on a 5 
× 5 cm sheet of medical tape. Between the cotton pad and the tape, a layer of plastic-film was added to 
inhibit the evaporation of the solutions. This configuration was applied for 20 min while the subjects 
were in a ≈30° incline position with their arms supinated. To assure that the applied substances did not 
interact or showed instability in the vehicle nuclear magnetic resonance spectroscopy (NMR) was 
performed on the vehicle, the individual solutions f 40% L-menthol and 10% CA and the combined 
solution containing both 40% L-menthol and 10% CA. The NMR spectra were recorded in CDCl3 on a 
Bruker AVIII-600 spectrometer with a 5 mm TCI (H–C/N–D) probe at 298 K. The NMR confirmed 
that the utilized substances are stable in the applied solutions and do not partake in any chemical 
reactions with the vehicle or each other, demonstrated by the lack of new peak formation in the mixture 
solution, see supplementary material 1, fig. 1-4.  
  
2.3. Pain assessment during application  
The primary outcome of the study was evoked peak pain intensity during the 20 min of application 
of the two substances. The participants were requird to rate the overall pain intensity on a visual 
analog scale (VAS) every 1 min (ranging from “no pain” = 0, to “worst imaginable pain” = 10) and to 
apply qualitative pain descriptors based on the validated brief descriptive Danish version of the McGill 
Pain Questionnaire (MPQ) at time points of 5, 10, 15 and 20 min.47 ‘Hot/burning’ and ‘cold/freezing’ 
were re-added to this modified edition of the questionnaire. 
 
2.4. Perceived area of pain  
At the first time point of a decrease in spontaneous pain intensity (i.e. corresponding to the 
individual peak pain level), the subjects marked the area of perceived pain on a digital generalized arm-
chart using a 10.1" Samsung Note tablet (Samsung Electronics, South Korea) equipped with Navigate 
Pain software version 1.9.1 (Aalborg University, Aalborg, Denmark) for further analysis of the spatial 
pain profile.9 The subjects were instructed to draw the area fromwhich pain was sensed irrespective of 
area of redness, innocuous sensations such as warmth nd the knowledge of the location of the 
application pad. The area of pain was later calculated with Navigate Pain as a percentage of the total 
chart area.  
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2.5. Quantitative sensory testing (QST) 
The QST protocol was partly derived from the QST guidelines of the German Research Network 
on Neuropathic Pain (DFNS).51 The verbal instructions (in Danish) for participants from the DFNS 
protocol were derived from the supplementary materils of Olsen et al. (2014). 43 The terminology used 
to describe the induced sensory derangement are define  in Sandkühler (2009).53 
2.5.1. Thermal thresholds: Tests for cold detection threshold (CDT), warmth detection threshold 
(WDT), cold pain threshold (CPT), and heat pain thres old were performed with a Medoc Pathway 
(Medoc Ltd, Ramat Yishay, Israel) equipped with a 3 ×  cm advanced thermal stimulator probe where 
the baseline temperature was set to 32 °C.  Ramp sti uli of 1 °C/s were delivered and when the 
subjects identified the associated threshold he/she pressed a button that returned the temperature to the 
baseline at a rate of 5 °C/s. The test result was calculated as the arithmetic mean of the outcome from 
three repeated stimuli.  
2.5.2. Mechanical sensitivity: The mechanical detection threshold (MDT) was determined using a set 
of 20 calibrated Von Frey filaments (North Coast Medical, Gilroy, CA, USA) with exerted forces 
ranging from 0.008 g to 300 g (0.078 mN to 2.9 N) applied over three series of stimuli with 
ascending/descending weight. Each stimulus lasted 1-2 s and intervals between stimuli were 
approximately 2 s. The subjects were asked to report upon any sensation from the area. The resulting 
MDT was calculated as the geometric mean of the values obtained in each of the five series of stimuli. 
To evaluate the mechanical pain threshold (MPT) and mechanical pain sensitivity, an electronic von 
Frey transducer and an electronic coVAS connected to a SENSE-Box setup were used (both items: 
Somedic, Hörby, Sweden). Five ramp stimuli from 0-110 g at a rate of 5g/1 sec with the default 
stimulus probe were conducted at different locations within the application area. The subjects were 
instructed to continuously rate the perceived pain on the coVAS ranging from “No pain” (0) to “worst 
imaginable pain” (10). The arithmetic mean of the VAS scores yielded three MPTs (fixed to VAS = 
0.5, 1 and 2) and an area-under-the-curve (AUC). To map the area of secondary mechanical 
hyperalgesia (SH) in response to pin prick stimulation, a set of 9 pinprick stimulators (Aalborg 
University, Aalborg, Denmark) were used. A pin was selected based on the MPT of each individual 
subject. Stimuli were applied from eight different paths arranged octagonally around the application 
area in steps of 1 cm at intervals of 2 s. Stimulation started approximately 6 cm away from the 
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application area and continued towards the application site until the volunteer reported an increase in 
sharp/pricking pain.  
2.6. Neurogenic inflammation (vasomotor responses) 
Before (baseline) and immediately following substance application, infrared thermography (A40 
Thermocamera, FLIR Systems, Wilsonville, OR, USA) and speckle contrast flowmetry (MoorFLPI, 
Moor Instruments, Devon, UK) were performed. Infrared thermography was conducted at a 40-cm 
distance between the camera lenses and the application area with an exposure time of 18 ms. Pictures 
were analyzed on the proprietary software using the arithmetic mean of the temperature in the 3 x 3 cm 
application area as region of interest (ThermaCAM Researcher Pro 2.10, FLIR Systems, Wilsonville, 
OR, USA). The perfusion assessment was conducted with a 30-cm distance between the head of the 
laser and the application area with an exposure timof 8.3ms. Single frame images were analyzed on 
appertaining software (MoorFLPI Review V 4.0, Moor Instruments), upon which the arithmetic mean 
flux (arbitrary units) was calculated. The longitudinal analysis of the spatial dispersion of neurogenic 
inflammation was performed using the line histogram tool. A 7-cm line centered in the area of 
application was placed longitudinally along the volar forearm and the perfusion intensity was recorded 
every 2.5 mm, an approach described in details previously.43 This allows for quantification of increased 
superficial blood perfusion both within the area of application (primary flare) and beyond the 
application area (secondary flare).  
2.7. Statistics 
Sample size calculations were conducted based on previously obtained data applying similar pain 
models 43 and using the approached outlined in 37 for crossover designs. The obtained data are 
presented as arithmetic or geometric means (non-linear stimulus modes) ± the standard error of the 
mean (SEM), unless otherwise stated. Data from all assessments were tested for normality using the 
Shapiro-Wilk normality test with and without log-transformation (MDT and pain area data remained 
non-normal). Average and peak pain intensity (primay outcome) were calculated and compared from 
VAS-recordings while categorical variables are shown as % -distribution without further hypothesis 
testing. Secondary outcome variables with 2 measurements were compared using the Student t-test or 
the Wilcoxon rank-sum test (non-parametric data), i.e. data from VAS-recording, area assessment 
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(non-parametric) and quantification of SH. Variables with 3 measurements or more were analyzed with 
RM-ANOVA using the Bonferroni post-hoc test, i.e. measures of mechanical sensitivity (with the 
exception of SH), thermal sensitivity, superficial blood perfusion and skin temperature. In addition to 
the pairwise post-hoc tests of the FLPI data the AUC was calculated and statistically evaluated for each 
individual data point. Correlational analyses where performed between parameters of spontaneous pain 
intensity and thermal, mechanical and blood flow aberrations using Pearson product-moment 
correlation coefficient (parametric data) or Spearman's rank correlation coefficient (non-parametric 
data). Both absolute and relative QST values were ass ssed for associations. Data handling and 
calculation of descriptive statistics were carried out in Excel, while statistical comparisons were 
performed in SPSS (Both software packages: Windows, Redmond, WA, USA). A p-value (P) ≤ 0.05 
was considered significant. 
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3. Results 
All enrolled participants finished the study and topical application of CA and L-menthol was well 
tolerated and did not produce unexpected or unwanted side effects (such as local edema or systemic 
reactions). The mechanical threshold data obtained from one outlier (participant no. 9) was excluded 
because MPT levels (see section 2.5.2) at baseline wer  not reached during the devised stimulus 
paradigm. No significant differences were observed related to randomization or arm dominancy. The 
study was not designed to detect potential gender diff ences. While the average peak pain score 
(primary outcome) for 10% CA was < 3, a total 9/14 subjects had peak pain scores ≥ 3. However, 3 
individuals reported pain peak values ≤ VAS 1. Unless specifically stated, these low responding 
individuals are included in the results below.    
 
3.1. Spontaneous pain intensity and quality 
CA produced mild pain (see fig. 2A and C), peaking after approximately 16 min of application, as 
2.84 ± 0.42 for CA and 2.10 ± 0.32 (on VAS 0-10) for CA + L-menthol. CA-evoked cutaneous pain 
was partially relieved by co-application of L-menthol (P ≤ 0.01, paired student t-test). If excluding the 
three subjects with peak pain intensity scores of ≤ 1, the peak pain intensity for the remaining group 
was 3.87 ± 0.46 for the CA and 3.05 ± 0.57 for the CA + L-menthol condition (P ≤ 0.05). The spatial 
and temporal pattern of the pain was not significantly altered by concomitant administration of L-
menthol (fig. 2D and F). However, observationally it appears that CA alone gave rise to a more 
homogeneous spatial profile (see fig. 2F), but this tendency was not quantified. A noteworthy positive 
correlation was observed between pain intensity after CA application and pain area size (ρ = 0.592, P = 
0.026), however, this association was not significant in the CA + L-menthol group. 
During application of CA the most common qualitative descriptors from the MPQ were 
“pricking/stinging” (54%), “warm/burning” (43%), “cold/freezing” (40%), “searing” (31%) and 
“itching” (26%). During co-application of CA and L-menthol the most frequent descriptors applied 
were “cold/freezing” (69%), and “searing” (38%), see fig. 2C. Paradoxically, “warm/burning” and 
“cold/freezing” were occasionally reported simultaneously during both CA and CA + L-menthol 
application.  
 
3.2. Thermal thresholds 
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CDT was significantly increased by the solution containing both CA and L-menthol, but not CA 
alone, in accordance with previous findings, (P ≤ 0.01, fig. 3A). WDT was increased after application 
of CA (fig. 3B). Concomitant application of L-menthol re-established WDT to the baseline levels (P ≤ 
0.05). As expected, CA + L-menthol drastically reduced CPT from 12.87 ± 2.49 °C at baseline to 20.43 
± 2.01 °C. (P ≤ 0.01). Administration of CA alone also induced cold hyperalgesia (P ≤ 0.05), although 
not to the same extent as the solution containing L-menthol (fig 3C). HPT was significantly decreased 
following CA administration, but was unchanged under L-menthol co-administration; however, an 
insignificant trend towards an HPT decrease was observed (P = 0.077). In summary, L-menthol had a 
counteractive effect on increased warmth and heat pain sensitivity while establishing or aggravating 
aberrations pertaining to innocuous and non-noxious cold sensation (see fig. 3 for an overview).  
 
3.3. Mechanical sensitivity 
MPT was decreased by CA at VAS=1 and 2 (P ≤ 0.05), but not significantly at VAS=0.5. 
Moreover, at VAS=1 co-administration of CA + L-menthol led to a reduction in MPT (fig. 4A). When 
comparing MPS AUC for the entire stimulus response function, no significant differences were found 
(fig. 4B), i.e. supra-threshold mechanical sensitivity was unaltered by co-application of L-menthol. An
average area of 29.43 ± 2.03 cm2 of SH was induced by topical CA administration. Co-application of 
L-menthol resulted in a significantly smaller area of SH (P ≤ 0.01, paired Student t-test) measuring 
15.43 ± 2.06 cm2, indicative of typical counter-irritancy since hig-concentration L-menthol alone has 
previously been shown to induce large areas of SH 8 (fig. 4C). No significant changes from baseline 
were observed in MDT following application of CA or CA + L-menthol (an insignificant trend towards 
a decrease in mechanical sensitivity was observed with CA alone (P = 0.089, fig 4D).  
 
3.4. Skin temperature and cutaneous perfusion (neurogenic inflammation) 
Strong neurogenic inflammation, as evidenced by increased cutaneous blood perfusion, was 
observed following the application of CA alone and CA + L-menthol. However, when comparing the 
results from the longitudinal dispersion of the perfusion, significant differences were observed 
particularly in the secondary area (see fig. 5A). While only minor differences in superficial perfusion 
produced by application of CA and CA + L-menthol were stablished within the primary area of 
application (grey area, fig. 5A), CA alone produced a very powerful secondary neurogenic flare, which 
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extended beyond 2 cm from the primary area of application (P ≤ 0.01). On the contrary, CA and L-
menthol applied together only produced a very modest s condary neurogenic flare.  
Skin temperature was increased by topical application of CA and CA + L-menthol (p < 0.01, fig. 
5B). However, there was no significant difference between the temperature increase induced by the two 
substances.   
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4. Discussion 
High concentration L-menthol has been widely used as a human pain model particularly for cold 
hyperalgesia. In the present study we sought to evaluate the analgesic, anti-hyperalgesic and anti-
inflammatory effect of L-menthol to CA-induced sensory and vasomotor symptomatology, and as such 
did not include a condition with L-menthol alone, which is well known to induce prolonged cold 
hyperalgesia, spontaneous pain and primary and secondary hyperalgesia.3,8,34,43,50,62,63 
Topical application of 10% CA provoked mild pain, primary and secondary mechanical 
hyperalgesia, heat and cold hyperalgesia and substantial primary and secondary neurogenic 
inflammation. Notably, 3 subjects were considerably below the averagely reported pain peak values 
and scored ≤ 1 (0.80 ± 0.05) on the VAS versus 3.87 ± 0.46, for the remaining 11 subjects. This could 
be indicative of a CA non-/low-responding phenotype, but a larger study is needed to assess whether or 
not this is in fact a distinct subgroup or merely a consequence of natural inter-individual variability. 
Simultaneous administration of 40% topical L-menthol ogether with CA completely or partially 
reversed spontaneous pain, primary and secondary mechanical hyperalgesia, heat hyperalgesia and 
neurogenic inflammation (temperature and blood perfusion), but aggravated cold hyperalgesia. In other 
words, L-menthol had a significant inhibitory effect on the primary outcome (peak pain intensity 
induced by CA) and a number of secondary outcome related to thermal and mechanical sensitivity and 
neurogenic inflammation. Below, fig. 6 summarizes the wo most likely potential mechanisms behind 
the observed antagonistic effect, i.e. either through spinal segmental inhibition or through peripheral 
receptor-mediated antagonism. It should be noticed that these could likely working in a complementary 
fashion.  
 
4.1. Spontaneous pain intensity and quality 
Application of 10% topical CA induced a mild spontaeous pain in this study, see fig. 2a and b. 
These findings are well in line with previous reports on topical CA in a 10% concentration as human 
surrogate model of pain, although the level of induced pain differ somewhat between studies, i.e. peak 
VAS0-10 = 3±0.7 
40 (non-responders excluded), peak VAS0-10  ≈3.7±0.6 
39, VAS0-10 = 2.3±0.63 
50 and 
NRS1-100 = 10.3±2.8 
43, which is likely related to small methodological differences, such as applied pain 
quantification, sampling frequency and participants. While 9/14 subjects did report peak pain > 3, 10% 
CA appear to induce mild pain on average. This mild inflammatory cutaneous pain bears resemblance 
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to inflammatory dermatological conditions such as atopic eczema or contact dermatitis, which beyond 
chronic itch is often characterized by mild pain.10,41 Notably, the pathoetiology of these conditions have 
also been tightly associated with TRPA1.14,42,52 In lieu of the significant differences in pain processing, 
pain sensitivity and TRP-expression between different tissues and anatomical locations 13,27,35,36, the 
CA pain model probably needs to be re-implemented in various tissues if to, for instance, mimic 
mucosal inflammation and pain associated with e.g.,throat soreness.   
In a subgroup of participants CA induced significant itch, a sensation likely partially masked by 
the presence of pain, since itching is shown to increase with lower topical CA concentration. 25 With 
co-administration of L-menthol, the pain quality shifted towards a “cold/freezing” character due to the
sensitizing effect of L-menthol on TRPM8+ cold-mediating fibers (Peier et al., 2002; Wasner et al., 
2004). Mechanistically, CA-induced pain is likely mediated by activation of TRPA1+ C-fibers, which 
partially co-localize with TRPV1 on nociceptive mechano-insensitive and polymodal C-fibers.40,54,58 It 
is conceivable that the reduction in pain intensity by co-application of L-menthol observed in the 
present study, is a consequence of TRPM8+ Aδ-fiber-mediated segmental inhibition of nociceptive C-
fiber transduction, since L-menthol, being a chemical proxy of cooling, does not possess the anti-
edematous or nerve conduction inhibitory effects of actual cold-induced analgesia.17 Supporting this 
notion, a recent in vivo study using 10% and 40% L-menthol suggested that TRPM8 is the principal 
mediator of L-menthol-induced analgesia in neuropathic pain associated with spinal nerve ligation. 45 
However, it has been proposed that analgesic effect o  L-menthol may include several mechanisms, 
such as desensitization of TRPV1-fibers, stimulation of κ-opioid receptors and enhancement of central 
glutamate-facilitated gate-control mechanisms.21,29,33,49,67  
 
4.2. Thermal thresholds  
Cold hyperalgesia was established by both CA and more significantly with simultaneous CA + L-
menthol administration due to its established interactions with cold receptor TRPM8+, indicating that 
L-menthol acts to increase pain sensitivity on thisparticular parameter. As for the L-menthol 
containing solution this is well in line with previous results.4,8,63 However, CA, herein found to induce 
cold hyperalgesia has previously been found to produce contradictory CPT results including cold 
hypoalgesia, cold hyperalgesia or simply no significant alterations.3,39,40,43,50 Cold pain sensation is 
hypothesized to rely on a mutual nociceptive pathway for both nociceptive heat and cold producing a 
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sensation of burning pain, with simultaneous activation of innocuous cold Aδ-fibers acting as a 
modality switch.5,12 Upon application of CA alone, but not combinatorial application of CA + L-
menthol, the HPT was significantly decreased, suggesting that L-menthol partly reverses CA-induced 
heat hyperalgesia. This is well in line with previous results from studies on the somatosensory effects 
of high-concentration L-menthol suggesting that it decreases HPT without pre-established heat 
hyperalgesia, potentially through sensitization of TRPV3 8,39,40, as is the case in this study. CDT was 
found to increase the response to the CA + L-menthol, but not to CA alone, while WDT was decreased 
by CA alone, indicative of sensitization of non-noxious primary afferent conveying warmth, but not by 
L-menthol + CA, in lines with L-menthol having cooling properties and CA inducing warm/burning 
sensations. Although a convenient organic solvent, ethanol has been shown to induce subtle 
somatosensory aberrations in itself particularly with regards to thermal detection thresholds 39,40,43,63, 
which may also be the case in this study. As evidenced by in vitro data, the modulatory properties of 
ethanol on somatosensation is proposed to be either directly through TRPV1 sensitization 59 or 
indirectly through dissolution of the outer epidermal layers.32   
 
4.3. Mechanical thresholds 
 
MPTs at VAS 1 was decreased by CA and CA + L-menthol, which is overall in accordance with 
the literature.8,40,63 At VAS 2, only CA alone produced a significantly decreased MPT highlighting a 
more pronounced effect on mechanoception than combinatorial application of CA and L-menthol and 
implying an antagonistic interaction between the two substances. A similar, but insignificant, trend (P 
= 0.089) was observed in MPS, indicating a minimal anti-hyperalgesic effect of L-menthol at 
suprathreshold stimulation-intensities. Mechanistically, the reduced pinprick hyperalgesia associated 
with combinatorial administration of L-menthol and CA is suggested to rely on L-menthol-induced 
local counter-irritancy through TRPV1 nociceptor desensitization or segmental Aδ-fiber-facilitated 
inhibition of mechanical pain perception.21,33,45,63 Not previously shown, co-administration of L-
menthol decreased the SH established by CA. Since SH is generally recognized to be a centrally 
mediated mechanism2,30,48, this is likely a consequence of an overall diminished nociceptive drive, i.e. 
through decreased spontaneous pain and neurogenic inflammation. MDT remained unaffected in this 
study plausibly because neither CA nor L-menthol sufficiently affected tactile C- or Aβ-fiber activity.8 
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4.4. Neurogenic inflammation 
In line with previous studies 25,39,40,43, topical application of CA induced neurogenic inflammation 
both within the area of application (primary flare) and substantially beyond the application area 
(secondary flare). This increased was also reflected on increased skin temperatures. Neurogenic 
inflammation is produced upon stimulation of peptidergic nociceptive or pruriceptive fibers, which 
release locally acting vasodilatory peptides, most prominently calcitonin gene-related peptide and 
substance P.31,54 Both polymodal fibers and mechano-insensitive-fibers are capable of producing 
neurogenic inflammation, but only mechano-insensitive-f bers have the ability to produce significant 
secondary flare since their terminal branching makes up a much larger receptive field than that of 
polymodal fibers. It has previously been shown thatL-menthol alone produces a small but significant 
increase in superficial blood flow 43,63, likely because approximately 15% of TRPM8+ cold-responsive 
mouse dorsal root ganglion neurons co-express TRPV1, or due to direct modulation of vascular 
tone.8,61 The strong neurogenic flare and pain induced by CA are likely consequences of a 50% C-fiber 
co-expression between TRPA1+ and peptidergic TRPV1+ fibers, since the pruriceptive TRPV1- 
population of TRPA+ fibers are normally non-peptidergic Mas-related G-protein coupled receptor-
positive X1, incapable of producing neurogenic inflammation as shown by 7,56,64,68. Interestingly, co-
administration of CA and L-menthol caused a primary flare reaction very similar to that of CA alone, 
but significantly decreased the secondary neurogenic flare suggestive of a specific local inhibitory 
effect of L-menthol on axon-reflex-flare producing mechano-insensitive nociceptors. Since TRPA1 is 
also a key player in pulmonary detection and reaction to irritants and in the non-histaminergic itch, this 
could also explain the known antitussive, decongestant and anti-pruritic effect of L-menthol.1,11,16 
Despite the fact that L-menthol is being widely used as an OTC analgesic, antipruritic, decongestant 
and antitussive, little is known regarding its mechanism of action in these contexts on a cellular level. 3 
The anti-hyperalgesic and anti-inflammatory effect observed in this study on is likely mediated by 
reduction of activity in the primary afferent neurons with potential explanations including interaction 
on the level of penetration, keratinocyte responses or receptor-desensitization. A human study using 
capsaicin found that L-menthol significantly cross-desensitized capsaicin-responsive C-fibers 
suggesting this response as a peripherally mediated counter-irritancy.21 TRPA1-stimulation with 
topical CA in humans has been shown to cause 25- to 42-f ld increases in local secretion of 
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eicosanoids and cytokines such as prostaglandin D2 and interleukin 8, respectively (VanderEnde and 
Morrow, 2001). Cellular interactions between TRPM8+ and TRPA1+ nerves and keratinocytes could 
alter secretion of pro-inflammatory substances, hence accounting for the herein observed effect of 
topical L-menthol.33,67 It is important to infer that higher concentrations of L-menthol, as applied in the 
present study, have been suggested also to act on TRPA1-receptors. Evidence from patch clamp 
recordings indicates that L-menthol interacts with TRPA1 in a bimodal concentration-dependent 
manner in which high concentrations reversibly block TRPA1-channels.28,33 This is a likely explanation 
for the decrease in neurogenic inflammation, which is known to be an entirely local neurogenic reflex 
22, but could also explain decreases in spontaneous pain, thermal and mechanical sensitivity. This is 
well in line with the fact that several ongoing clinical studies are currently focusing on TRPA1-
antagonists for conditions such as pain and pruritus. The fact that L-menthol might not be an entirely 
TRPM8-specific compound 28,33,55 means that it could interact independently of TRPM8 with pro-
inflammatory mediators to, at least in part, create the observed effects. This might be aggravated by 
higher concentrations, which makes it desirable to t st novel and more potent TRPM8-agonists, such as 
icilin, when these become feasible to apply in humans.  
 
5. Conclusion 
Here it is shown, for the first time, that high cone tration L-menthol has significant alleviatory 
effects on inflammatory pain and associated sensory aberrations in a topical 10% CA-induced 
surrogate pain model assessed systematically by comprehensive quantitative sensory testing. Further 
studies are warranted to ascertain the mechanistic basis of the observed L-menthol-induced inhibition 
of CA-evoked neurogenic flare, pain and sensory hypersensitivity. These results suggest that novel and 
more potent TRPM8-agonists or dual action TRPM8-agonists/TRPA1-antagonists could be of benefit 
for anti-hyperalgesic and anti-inflammatory purposes. 
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Figure legends 
 
Fig. 1. A flowchart of the experimental session showing test arms, application of solutions for 20 min 
and the assessments conducted at different time points. Test arm and solutions are listed only as an 
exemplification - the actual order of substance application was randomized.  
 
Fig. 2. Changes in pain intensity, temporality, quality and spatiality in response to application of CA 
and CA + L-menthol: A) Temporal pain intensity, B) Average and peak pain intensity, C) Descriptive 
pain quality, D) Spatial distribution of pain at ind vidualized pain peaks, E) Duration until peak pain 
intensity, F) Overlays of the spatial distribution f pain. Asterisks: * = P ≤ 0.05, ** = P ≤ 0.01. 
 
Fig. 3. Baseline averages and changes in thermal thresholds in response to application of CA and CA + 
L-menthol: A) Cold detection threshold, B) Warmth detection threshold, C) Cold pain threshold and D) 
Heat pain threshold. Asterisks: * = P ≤ 0.05, ** = P ≤ 0.01. 
 
Fig. 4. Baseline averages and changes in mechanical thresholds, sensitivity and secondary hyperalgesia 
in response to application of CA and CA + L-menthol: A) Mechanical pain threshold at VAS = 0.5, 
VAS = 1 and VAS = 2. B) Mechanical pain sensitivity, C) Area of secondary hyperalgesia, D) 
Mechanical detection threshold. Asterisks: * = P ≤ 0.05, ** = P ≤ 0.01. 
 
Fig. 5. Changes in the superficial blood flow and temperature following application of CA and L-
menthol + CA. A) Longitudinal dispersion of neurogenic inflammation. The centered stippled line 
represents the center of the application area while t e grey zone represents the primary (application) 
area. The significance indication bars in the lower right corner of fig. A show significance between 
entire data series whereas individual asterisks denote comparison between each location. Both with 
Bonferroni-correction. B) Superficial skin temperature measured by thermography in the application 
area. Asterisks: * = P ≤ 0.05, ** = P ≤ 0.01.  
 
Fig. 6. Summary of suggested mechanisms (marked with “?”) behind the observed antagonism 
between TRPA1 and TRPM8-activation on sensory and vasomotor parameters. Since the axon-reflex is 
a peripheral response not affected by proximal anesthetic blockade 22, it is likely that different 
mechanisms could be involved in reducing the neurogenic inflammation, which is likely related to 
high-concentration L-menthol-associated TRPA1-antagonism, and in reducing sensory symptoms 
perhaps via segmental inhibition.  
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Highlights 
 
• Topical administration of 10% trans-cinnamaldehyde was applied to evoke pain, neurogenic inflammation, 
thermal hyperalgesia, and primary and secondary mechani al hyperalgesia 
• Simultaneous administration of 40% topical L-menthol completely or partially reversed pain, mechanical 
hyperalgesia, heat hyperalgesia and neurogenic inflammation, but aggravated cold hyperalgesia 
• We suggest that L-menthol’s well-known counter-irritant effect is mediated in in part through spinal 
segmental inhibition and through peripheral receptor-mediated antagonism 
• Potent TRPM8-agonists could be useful as topical anti-hyperalgesics and anti-inflammatories   
 
